{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:31:18Z","timestamp":1793827878014,"version":"4.6.1"},"reference-count":131,"publisher":"Becaris Publishing Limited","issue":"8","funder":[{"name":"Ascentage Pharma Group Corp Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To conduct a systematic literature review of real-world evidence on the burden of tyrosine kinase inhibitor (TKI) failure in Chinese patients with chronic myeloid leukemia (CML).\n            <jats:bold>Methods:<\/jats:bold>\n            We identified 155 references in Chinese- and English-language journals from 2001 to 2021.\n            <jats:bold>Results:<\/jats:bold>\n            The age-adjusted mortality rate in Chinese CML patients was decreasing. Imatinib treatment had a higher annual treatment failure risk than nilotinib (0.199 vs 0.041). Patients with TKI treatment failure tended to be young (median: 38.6\u00a0years), have progressive disease (44.3%) and harbor\n            <jats:italic>BCR-ABL1<\/jats:italic>\n            mutations (51.6%). The disease burden of TKI treatment failure included reduced health outcomes and increased health resource utilization and costs.\n            <jats:bold>Conclusion:<\/jats:bold>\n            CML relapse cases could continuously rise in China due to increasing TKI treatment failure over extended survival.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0032","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T09:33:07Z","timestamp":1649755987000},"page":"621-637","source":"Crossref","is-referenced-by-count":4,"title":["Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review"],"prefix":"10.57264","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3341-8193","authenticated-orcid":false,"given":"Yanli","family":"Zhang","sequence":"first","affiliation":[{"name":"Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-4745","authenticated-orcid":false,"given":"Wendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Normin Health Consulting, Ltd., Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Pathak","sequence":"additional","affiliation":[{"name":"Ascentage Pharma Group, Inc., Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Yang","sequence":"additional","affiliation":[{"name":"Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China"},{"name":"State Key Laboratory of Oncology, South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhai","sequence":"additional","affiliation":[{"name":"Ascentage Pharma Group, Inc., Rockville, MD, USA"},{"name":"Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"8","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","article-title":"Chronic myelogenous leukemia","volume":"286","author":"Kalidas M","year":"2001","unstructured":"Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 286(8), 895\u2013898 (2001).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker BJ","year":"2000","unstructured":"Druker BJ, Lydon NB. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105(1), 3\u20137 (2000).","journal-title":"J. Clin. Invest."},{"issue":"10","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376(10), 917\u2013927 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour EJ","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin. Lymphoma Myeloma Leuk. 13(5), 515\u2013529 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"e_1_3_5_7_2","first-page":"353","article-title":"The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)","volume":"41","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Hematology, Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition). Zhonghua Xue Ye Xue Za Zhi. 41(5), 353\u2013364 (2020).","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"issue":"1","key":"e_1_3_5_8_2","first-page":"90","article-title":"Hematopoietic stem cell transplantation in China: current status and prospects","volume":"1","author":"Huang XJ","year":"2011","unstructured":"Huang XJ. Hematopoietic stem cell transplantation in China: current status and prospects. Am. J. Blood Res. 1(1), 90\u201397 (2011).","journal-title":"Am. J. Blood Res."},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby D","year":"2011","unstructured":"Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25, 7\u201322 (2011).","journal-title":"Leukemia"},{"issue":"5","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3324\/haematol.2012.068890","article-title":"The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia","volume":"98","author":"Lange T","year":"2013","unstructured":"Lange T, Ernst T, Gruber FX The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica 98(5), 714\u2013717 (2013).","journal-title":"Haematologica"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman AE","year":"2021","unstructured":"Osman AE, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Reviews 49, 100825 (2021).","journal-title":"Blood Reviews"},{"key":"e_1_3_5_12_2","unstructured":"Wells GA Shea B O\u2019Connell D The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (2011). www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"580759","DOI":"10.3389\/fonc.2020.580759","article-title":"Global, regional, and national burden of chronic myeloid leukemia, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"10","author":"Lin Q","year":"2020","unstructured":"Lin Q, Mao L, Shao L Global, regional, and national burden of chronic myeloid leukemia, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Front. Oncol. 10, 580759 (2020).","journal-title":"Front. Oncol."},{"key":"e_1_3_5_14_2","first-page":"484","article-title":"Analysis of the characteristics and trends of the main subtypes of leukemia in Shanghai","volume":"16","author":"Bao PP","year":"2017","unstructured":"Bao PP, Wu CX, Zhang ML Analysis of the characteristics and trends of the main subtypes of leukemia in Shanghai. J. Diagn. Concepts Pract. 16, 484\u2013491 (2017).","journal-title":"J. Diagn. Concepts Pract."},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/ijc.29591","article-title":"A retrospective cohort study of cause-specific mortality and incidence of hematopoietic malignancies in Chinese benzene-exposed workers","volume":"137","author":"Linet MS","year":"2015","unstructured":"Linet MS, Gilbert ES, Dores GM A retrospective cohort study of cause-specific mortality and incidence of hematopoietic malignancies in Chinese benzene-exposed workers. Int. J. Cancer 137, 2184\u20132197 (2015).","journal-title":"Int. J. Cancer"},{"key":"e_1_3_5_16_2","first-page":"260","article-title":"Analysis on the incidence of leukemia among workers in Shajing in Shenzhen","volume":"15","author":"Hua JJ","year":"2014","unstructured":"Hua JJ, Xu ZK, Du JK, Han JH, Jia DD, Liang H. Analysis on the incidence of leukemia among workers in Shajing in Shenzhen. Chin. Prev. Med. 15, 260\u2013263 (2014).","journal-title":"Chin. Prev. Med."},{"issue":"4","key":"e_1_3_5_17_2","first-page":"281","article-title":"Severe hematological adverse reactions during the period of taking tyrosine kinase inhibitors in patients with chronic myelogenous leukemia and their effects on treatment response","volume":"40","author":"Yu L","year":"2019","unstructured":"Yu L, Qin YQ, Lai YY, Shi HX, Huang XJ, Jiang Q. Severe hematological adverse reactions during the period of taking tyrosine kinase inhibitors in patients with chronic myelogenous leukemia and their effects on treatment response. Chin. J. Hematol. 40(4), 281\u2013287 (2019).","journal-title":"Chin. J. Hematol."},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4274\/tjh.2016.0156","article-title":"Changing treatment may affect the predictive ability of European treatment outcome study scoring for the prognosis of patients with chronic myeloid leukemia","volume":"34","author":"Huang J","year":"2017","unstructured":"Huang J, Wang L, Chen L Changing treatment may affect the predictive ability of European treatment outcome study scoring for the prognosis of patients with chronic myeloid leukemia. Turk. J. Hematol. 34, 10\u201315 (2017).","journal-title":"Turk. J. Hematol."},{"key":"e_1_3_5_19_2","first-page":"1197","article-title":"The efficacy and safety of imatinib or nilotinib in the first-line treatment of elderly patients with chronic myeloid leukemia in the chronic phase","volume":"8","author":"Zhang JJ","year":"2019","unstructured":"Zhang JJ, Yang LJ, Zhu Y The efficacy and safety of imatinib or nilotinib in the first-line treatment of elderly patients with chronic myeloid leukemia in the chronic phase. J. Nanjing Med. Univ. (Nat. Sci.) 8, 1197\u20131201 (2019).","journal-title":"J. Nanjing Med. Univ. (Nat. Sci.)"},{"key":"e_1_3_5_20_2","first-page":"875","article-title":"Real-world evidence of molecular response to tyrosine kinase inhibitors from China supports European LeukemiaNet 2013 recommendations for the management of chronic myeloid leukaemia","volume":"2","author":"Yin H","year":"2018","unstructured":"Yin H, Chen Y, Chen L Real-world evidence of molecular response to tyrosine kinase inhibitors from China supports European LeukemiaNet 2013 recommendations for the management of chronic myeloid leukaemia. Hemasphere 2, 875\u2013876 (2018).","journal-title":"Hemasphere"},{"issue":"5","key":"e_1_3_5_21_2","first-page":"395","article-title":"Multivariate analysis of drug resistance during the treatment of chronic myelogenous leukemia with imatinib","volume":"34","author":"Zhou M","year":"2013","unstructured":"Zhou M, Qiu HY, He GS Multivariate analysis of drug resistance during the treatment of chronic myelogenous leukemia with imatinib. Chin. J. Hematol. 34(5), 395\u2013398 (2013).","journal-title":"Chin. J. Hematol."},{"key":"e_1_3_5_22_2","first-page":"4","article-title":"Clinical observation of the effect of clonal chromosomal abnormalities in Philadelphia chromosome-negative cells on the curative effect of chronic myeloid leukemia","volume":"803","author":"Zhao HF","year":"2019","unstructured":"Zhao HF, Zhang YL, Zu YL Clinical observation of the effect of clonal chromosomal abnormalities in Philadelphia chromosome-negative cells on the curative effect of chronic myeloid leukemia. Chin. J. Intern. Med. 803, 4\u20137 (2019).","journal-title":"Chin. J. Intern. Med."},{"key":"e_1_3_5_23_2","first-page":"479","article-title":"Adverse hematological reactions in 435 patients with chronic myeloid leukemia after treatment with imatinib mesylate","volume":"12","author":"Wang J","year":"2015","unstructured":"Wang J, Gao SK, Li Z, Li MJ, Zhang LL, Song YP. Adverse hematological reactions in 435 patients with chronic myeloid leukemia after treatment with imatinib mesylate. J. Leuk. Lymphoma 12, 479\u2013482 (2015).","journal-title":"J. Leuk. Lymphoma"},{"key":"e_1_3_5_24_2","first-page":"87","article-title":"The clinical dose and efficacy of imatinib in the treatment of chronic myeloid leukemia","volume":"11","author":"Chen J","year":"2017","unstructured":"Chen J. The clinical dose and efficacy of imatinib in the treatment of chronic myeloid leukemia. World Clin. Med. 11, 87\u201388 (2017).","journal-title":"World Clin. Med."},{"issue":"5","key":"e_1_3_5_25_2","first-page":"339","article-title":"Comparative analysis of the prognostic system and factors of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"48","author":"Zhang CJ","year":"2020","unstructured":"Zhang CJ, Zheng XL, Zheng DD, Xia WL, Su XL. Comparative analysis of the prognostic system and factors of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Chin. Youjiang Med. J. 48(5), 339\u2013344 (2020).","journal-title":"Chin. Youjiang Med. J."},{"issue":"08","key":"e_1_3_5_26_2","first-page":"809","article-title":"Comparison of three prognostic scoring systems in evaluating the prognosis of chronic myeloid leukemia","volume":"41","author":"Huang J","year":"2016","unstructured":"Huang J, Zhao XL. Comparison of three prognostic scoring systems in evaluating the prognosis of chronic myeloid leukemia. J. Central South Univ. (Med. Sci.) 41(08), 809\u2013814 (2016).","journal-title":"J. Central South Univ. (Med. Sci.)"},{"issue":"03","key":"e_1_3_5_27_2","first-page":"723","article-title":"The estimated value of different scoring systems for the clinical efficacy of newly diagnosed patients with chronic myeloid leukemia","volume":"27","author":"Wang PP","year":"2019","unstructured":"Wang PP, Zhang PP, Zhang J, Xi YM. The estimated value of different scoring systems for the clinical efficacy of newly diagnosed patients with chronic myeloid leukemia. J. Exp. Hematol. 27(03), 723\u2013728 (2019).","journal-title":"J. Exp. Hematol."},{"issue":"23","key":"e_1_3_5_28_2","first-page":"78","article-title":"Efficacy of the first and second generation TKIs in the treatment of chronic myeloid leukemia","volume":"32","author":"Yang AL","year":"2019","unstructured":"Yang AL, Liu X, Wang XB Efficacy of the first and second generation TKIs in the treatment of chronic myeloid leukemia. J. Med. Inf. 32(23), 78\u201381 (2019).","journal-title":"J. Med. Inf."},{"issue":"12","key":"e_1_3_5_29_2","first-page":"811","article-title":"Early effect of domestic imatinib mesylate in the treatment of chronic myelogenous leukemia patients","volume":"28","author":"Huang Q","year":"2016","unstructured":"Huang Q, Liu H, Li Y, Zhang XY, Wang XM. Early effect of domestic imatinib mesylate in the treatment of chronic myelogenous leukemia patients. Cancer Res. Clin. 28(12), 811\u2013814 (2016).","journal-title":"Cancer Res. Clin."},{"issue":"4","key":"e_1_3_5_30_2","first-page":"527","article-title":"Comparative analysis of clinical efficacy and drug safety of domestic imatinib and original imatinib in the treatment of newly diagnosed chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Zhang JZ","year":"2017","unstructured":"Zhang JZ, Bao Y, Chen SM Comparative analysis of clinical efficacy and drug safety of domestic imatinib and original imatinib in the treatment of newly diagnosed chronic myelogenous leukemia in the chronic phase. J. Clin. Hematol. 30(4), 527\u2013531 (2017).","journal-title":"J. Clin. Hematol."},{"issue":"07","key":"e_1_3_5_31_2","first-page":"566","article-title":"Comparison of the efficacy and safety of domestic and original imatinib in the treatment of newly diagnosed chronic myelogenous leukemia","volume":"38","author":"Jiang H","year":"2017","unstructured":"Jiang H, Zhi LT, Hou M, Wang JX, Wu DP, Huang XJ. Comparison of the efficacy and safety of domestic and original imatinib in the treatment of newly diagnosed chronic myelogenous leukemia. Chin. J. Hematol. 38(07), 566\u2013571 (2017).","journal-title":"Chin. J. Hematol."},{"issue":"04","key":"e_1_3_5_32_2","first-page":"1162","article-title":"Curative efficacy of first generation TKI in the treatment of CML-CP combined with vPh and analysis of its genetic characteristics","volume":"28","author":"Tan L","year":"2020","unstructured":"Tan L, Xie Y, Yang J, Liu L. Curative efficacy of first generation TKI in the treatment of CML-CP combined with vPh and analysis of its genetic characteristics. J. Exp. Hematol. 28(04), 1162\u20131166 (2020).","journal-title":"J. Exp. Hematol."},{"issue":"5","key":"e_1_3_5_33_2","first-page":"811","article-title":"Follow-up observation of imatinib in the treatment of chronic myeloid leukemia in chronic phase","volume":"28","author":"Zhong JS","year":"2012","unstructured":"Zhong JS, Meng FY, Xu D Follow-up observation of imatinib in the treatment of chronic myeloid leukemia in chronic phase. J. Pract. Med. 28(5), 811\u2013813 (2012).","journal-title":"J. Pract. Med."},{"issue":"22","key":"e_1_3_5_34_2","first-page":"129","article-title":"Discussion on the safety and efficacy of imatinib in the treatment of patients with chronic myeloid leukemia","volume":"11","author":"Wang YM","year":"2016","unstructured":"Wang YM. Discussion on the safety and efficacy of imatinib in the treatment of patients with chronic myeloid leukemia. Chin. Pract. Med. 11(22), 129\u2013130 (2016).","journal-title":"Chin. Pract. Med."},{"key":"e_1_3_5_35_2","first-page":"646","article-title":"Long-term efficacy observation of imatinib in the treatment of 135 cases of chronic myeloid leukemia","volume":"11","author":"Zhou KS","year":"2010","unstructured":"Zhou KS, Wang CC, Zhao YZ Long-term efficacy observation of imatinib in the treatment of 135 cases of chronic myeloid leukemia. J. Leuk. Lymphoma 11, 646\u2013650 (2010).","journal-title":"J. Leuk. Lymphoma"},{"issue":"2","key":"e_1_3_5_36_2","first-page":"146","article-title":"Comparison of efficacy and drug resistance of tyrosine kinase inhibitors in chronic and advanced stages of chronic myelogenous leukemia","volume":"26","author":"Jin FF","year":"2018","unstructured":"Jin FF, Lai BB, Zhang YY, Xia HF. Comparison of efficacy and drug resistance of tyrosine kinase inhibitors in chronic and advanced stages of chronic myelogenous leukemia. Chin. J. Prev. Control Chronic Dis. 26(2), 146\u2013150 (2018).","journal-title":"Chin. J. Prev. Control Chronic Dis."},{"issue":"2","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1016\/j.clml.2019.12.001","article-title":"Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia","volume":"20","author":"Chen YL","year":"2020","unstructured":"Chen YL, Yin H, Chen LF Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 20(2), E43\u2013E49 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11684-015-0400-4","article-title":"Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase","volume":"9","author":"Xu L","year":"2015","unstructured":"Xu L, Zhu H, Hu J Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. Front. Med. 9, 304\u2013311 (2015).","journal-title":"Front. Med."},{"issue":"1","key":"e_1_3_5_39_2","first-page":"11","article-title":"Clinical analysis of nilotinib in the treatment of chronic myeloid leukemia resistant or intolerant to imatinib","author":"Wang AH","year":"2010","unstructured":"Wang AH, Zhou L, You JH, Wang L, Li JM, Hu J Clinical analysis of nilotinib in the treatment of chronic myeloid leukemia resistant or intolerant to imatinib. Chin. J. Hematol. (1), 11\u201315 (2010).","journal-title":"Chin. J. Hematol."},{"issue":"7","key":"e_1_3_5_40_2","first-page":"1000","article-title":"Long-term follow-up study of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia","volume":"32","author":"Wei YQ","year":"2012","unstructured":"Wei YQ, Zhang X, Chen WW, Cao R, Yin CX, Feng R Long-term follow-up study of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia. J. Southern Med. Univ. 32(7), 1000\u20131003 (2012).","journal-title":"J. Southern Med. Univ."},{"issue":"10","key":"e_1_3_5_41_2","first-page":"794","article-title":"Interferon combined with imatinib in the treatment of chronic myeloid leukemia with mutations in ABL kinase region","volume":"55","author":"Zu YL","year":"2016","unstructured":"Zu YL, Zhang YL, Zhou J Interferon combined with imatinib in the treatment of chronic myeloid leukemia with mutations in ABL kinase region. Chin. J. Intern. Med. 55(10), 794\u2013796 (2016).","journal-title":"Chin. J. Intern. Med."},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000495335","article-title":"Responses to dasatinib as a second- and third-line tyrosine kinase inhibitor in chronic phase chronic myeloid leukaemia patients","volume":"142","author":"Liu D","year":"2019","unstructured":"Liu D, Liu Y, Xue M Responses to dasatinib as a second- and third-line tyrosine kinase inhibitor in chronic phase chronic myeloid leukaemia patients. Acta Haematol. 142, 79\u201386 (2019).","journal-title":"Acta Haematol."},{"key":"e_1_3_5_43_2","first-page":"458","article-title":"Clinical analysis of nilotinib in the treatment of imatinib-resistant chronic myeloid leukemia","volume":"4","author":"Xu JJ","year":"2013","unstructured":"Xu JJ, Du X, Lou J Clinical analysis of nilotinib in the treatment of imatinib-resistant chronic myeloid leukemia. J. Clin. Hematol. 4, 458\u2013461 (2013).","journal-title":"J. Clin. Hematol."},{"issue":"6","key":"e_1_3_5_44_2","first-page":"1545","article-title":"Clinical study of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia patients","volume":"22","author":"Pan LQ","year":"2014","unstructured":"Pan LQ, Liu WX, Zhu Y Clinical study of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia patients. J. Exp. Hematol. 22(6), 1545\u20131549 (2014).","journal-title":"J. Exp. Hematol."},{"issue":"2","key":"e_1_3_5_45_2","first-page":"123","article-title":"To evaluate the effect of baseline ABL kinase region point mutations on the efficacy of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia","volume":"33","author":"Jiang H","year":"2012","unstructured":"Jiang H, Chen SS, Jiang B To evaluate the effect of baseline ABL kinase region point mutations on the efficacy of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia. Chin. J. Hematol. 33(2), 123\u2013126 (2012).","journal-title":"Chin. J. Hematol."},{"issue":"2","key":"e_1_3_5_46_2","first-page":"127","article-title":"Clinical outcome and influencing factors of patients with chronic myelogenous leukemia in the chronic phase receiving tyrosine kinase inhibitor treatment and clinical analysis","volume":"42","author":"Zhang D","year":"2019","unstructured":"Zhang D, Zhu HL. Clinical outcome and influencing factors of patients with chronic myelogenous leukemia in the chronic phase receiving tyrosine kinase inhibitor treatment and clinical analysis. Int. J. Blood Transfus. Hematol. 42(2), 127\u2013133 (2019).","journal-title":"Int. J. Blood Transfus. Hematol."},{"key":"e_1_3_5_47_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","article-title":"Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients","volume":"90","author":"Qin Y","year":"2011","unstructured":"Qin Y, Chen S, Jiang B Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann. Hematol. 90, 47\u201352 (2011).","journal-title":"Ann. Hematol."},{"issue":"6","key":"e_1_3_5_48_2","first-page":"1597","article-title":"Efficacy of TKI in the treatment of chronic myeloid leukemia and related influencing factors analysis of deep molecular response","volume":"25","author":"Jing Y","year":"2017","unstructured":"Jing Y, Yang L, Liu DH. Efficacy of TKI in the treatment of chronic myeloid leukemia and related influencing factors analysis of deep molecular response. J. Exp. Hematol. 25(6), 1597\u20131604 (2017).","journal-title":"J. Exp. Hematol."},{"key":"e_1_3_5_49_2","first-page":"471","article-title":"Analysis of the efficacy and safety of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia in the elderly in chronic phase","volume":"39","author":"Ren WR","year":"2016","unstructured":"Ren WR, Lu SJ, Ren NN, Li XL, Zhu HL. Analysis of the efficacy and safety of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia in the elderly in chronic phase. Int. J. Blood Transfus. Hematol. 39, 471\u2013475 (2016).","journal-title":"Int. J. Blood Transfus. Hematol."},{"issue":"22","key":"e_1_3_5_50_2","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1182\/blood.V128.22.5439.5439","article-title":"Baseline characteristics and early monitoring of Chinese CML patients treated with dasatinib: report from a multicenter, observational registry-based study","volume":"128","author":"Jiang Q","year":"2016","unstructured":"Jiang Q, Hu J, Zheng F Baseline characteristics and early monitoring of Chinese CML patients treated with dasatinib: report from a multicenter, observational registry-based study. Blood 128(22), 5439 (2016).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_5_51_2","first-page":"65","article-title":"Efficacy of switching to second-generation tyrosine kinase inhibitors in chronic myeloid leukemia patients with poor response to imatinib","volume":"23","author":"Qiao JH","year":"2015","unstructured":"Qiao JH, Zhang ZC, Yao B Efficacy of switching to second-generation tyrosine kinase inhibitors in chronic myeloid leukemia patients with poor response to imatinib. J. Exp. Hematol. 23(1), 65\u201369 (2015).","journal-title":"J. Exp. Hematol."},{"issue":"2","key":"e_1_3_5_52_2","first-page":"93","article-title":"Analysis of the efficacy and influencing factors of nilotinib and dasatinib as second and third-line drugs in the treatment of chronic myelogenous leukemia patients in the chronic and accelerated phases","volume":"41","author":"Yuan T","year":"2020","unstructured":"Yuan T, Lai YY, Qin YQ Analysis of the efficacy and influencing factors of nilotinib and dasatinib as second and third-line drugs in the treatment of chronic myelogenous leukemia patients in the chronic and accelerated phases. Chin. J. Hematol. 41(2), 93 (2020).","journal-title":"Chin. J. Hematol."},{"issue":"2","key":"e_1_3_5_53_2","first-page":"382","article-title":"Mean erythrocyte volume can be used as a predictor of the efficacy of chronic myeloid leukemia","volume":"26","author":"Lu L","year":"2018","unstructured":"Lu L, Qiao C, Hong M Mean erythrocyte volume can be used as a predictor of the efficacy of chronic myeloid leukemia. J. Exp. Hematol. 26(2), 382\u2013388 (2018).","journal-title":"J. Exp. Hematol."},{"key":"e_1_3_5_54_2","first-page":"469","article-title":"Distribution of BCR-ABL kinase region mutations in patients with tyrosine kinase inhibitor-resistant chronic myeloid leukemia and its influencing factors","volume":"41","author":"Shi DY","year":"2020","unstructured":"Shi DY, Qin YQ, Lai YY, Shi HX, Huang XJ, Jiang Q. Distribution of BCR-ABL kinase region mutations in patients with tyrosine kinase inhibitor-resistant chronic myeloid leukemia and its influencing factors. Chin. J. Hematol. 41, 469\u2013476 (2020).","journal-title":"Chin. J. Hematol."},{"issue":"3","key":"e_1_3_5_55_2","first-page":"364","article-title":"Clinical characteristics of T315I gene mutation in chronic myeloid leukemia and the efficacy of ponatinib","volume":"39","author":"Chen C","year":"2019","unstructured":"Chen C, Liao LB, Xu D Clinical characteristics of T315I gene mutation in chronic myeloid leukemia and the efficacy of ponatinib. J. Southern Med. Univ. 39(3), 364 (2019).","journal-title":"J. Southern Med. Univ."},{"key":"e_1_3_5_56_2","first-page":"287","article-title":"Clinical efficacy analysis of second-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"47","author":"Lu SJ","year":"2016","unstructured":"Lu SJ, Zhu HL, Li XL Clinical efficacy analysis of second-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. J. Sichuan Univ. (Med. Sci.) 47, 287\u2013291 (2016).","journal-title":"J. Sichuan Univ. (Med. Sci.)"},{"issue":"2","key":"e_1_3_5_57_2","first-page":"98","article-title":"Efficacy and safety analysis of domestic dasatinib in the second-line treatment of chronic myelogenous leukemia patients","volume":"40","author":"Chen YL","year":"2019","unstructured":"Chen YL, Wang L, Yuan GL Efficacy and safety analysis of domestic dasatinib in the second-line treatment of chronic myelogenous leukemia patients. Chin. J. Hematol. 40(2), 98 (2019).","journal-title":"Chin. J. Hematol."},{"issue":"12","key":"e_1_3_5_58_2","first-page":"996","article-title":"A comparative study of nilotinib and imatinib in the first-line treatment of patients with newly diagnosed chronic myelogenous leukemia","volume":"40","author":"Yu L","year":"2019","unstructured":"Yu L, Qin YQ, Lai YY A comparative study of nilotinib and imatinib in the first-line treatment of patients with newly diagnosed chronic myelogenous leukemia. Chin. J. Hematol. 40(12), 996 (2019).","journal-title":"Chin. J. Hematol."},{"key":"e_1_3_5_59_2","first-page":"569","article-title":"Analysis of related factors of point mutations in ABL kinase region in patients with TKI-resistant chronic myeloid leukemia","volume":"37","author":"Chen DY","year":"2021","unstructured":"Chen DY, Wang J, Zhang LD, Cheng Y, Zhang HB. Analysis of related factors of point mutations in ABL kinase region in patients with TKI-resistant chronic myeloid leukemia. J. Modern Med. Health 37, 569\u2013571 (2021).","journal-title":"J. Modern Med. Health"},{"key":"e_1_3_5_60_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s11596-018-1976-0","article-title":"Efficacy and safety of generic dasatinib as a second-line treatment for patients with chronic myeloid leukemia: a multicenter retrospective study in Hubei province, China","volume":"38","author":"Chen LF","year":"2018","unstructured":"Chen LF, Yuan GL, Zhong ZD Efficacy and safety of generic dasatinib as a second-line treatment for patients with chronic myeloid leukemia: a multicenter retrospective study in Hubei province, China. Curr. Med. Sci. 38, 1005\u20131011 (2018).","journal-title":"Curr. Med. Sci."},{"key":"e_1_3_5_61_2","first-page":"49","article-title":"Detection of ABL kinase region point mutations in patients with chronic myeloid leukemia after imatinib treatment","volume":"1","author":"Wu LL","year":"2010","unstructured":"Wu LL, Zeng QS, Yang MZ Detection of ABL kinase region point mutations in patients with chronic myeloid leukemia after imatinib treatment. J. Exp. Hematol. 1, 49\u201353 (2010).","journal-title":"J. Exp. Hematol."},{"key":"e_1_3_5_62_2","first-page":"647","article-title":"Clinical efficacy analysis of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"45","author":"Li XL","year":"2014","unstructured":"Li XL, Zhu HL, Liu HY Clinical efficacy analysis of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. J. Sichuan Univ. (Med. Sci.) 45, 647\u2013651 (2014).","journal-title":"J. Sichuan Univ. (Med. Sci.)"},{"issue":"2","key":"e_1_3_5_63_2","first-page":"110","article-title":"Comparison of the characteristics and efficacy of Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia with T315I mutation","volume":"37","author":"Wang J","year":"2016","unstructured":"Wang J, Zhang YL, Zu YL Comparison of the characteristics and efficacy of Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia with T315I mutation. Chin. J. Hematol. 37(2), 110 (2016).","journal-title":"Chin. J. Hematol."},{"key":"e_1_3_5_64_2","first-page":"1","article-title":"Study on the efficacy of imatinib in the treatment of chronic myelogenous leukemia","volume":"9","author":"Zhang F","year":"2020","unstructured":"Zhang F. Study on the efficacy of imatinib in the treatment of chronic myelogenous leukemia. Med. Community 9, 1 (2020).","journal-title":"Med. Community"},{"key":"e_1_3_5_65_2","first-page":"5","article-title":"Long-term survival analysis of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia","volume":"1","author":"Chen YK","year":"2010","unstructured":"Chen YK, Zhang Y, Liu QF Long-term survival analysis of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. J. Intern. Med. Concepts Pract. 1, 5 (2010).","journal-title":"J. Intern. Med. Concepts Pract."},{"issue":"8","key":"e_1_3_5_66_2","first-page":"3","article-title":"The morphological characteristics and prognosis of bone marrow cells in chronic myelogenous leukemia with acute granulosis and acute lymphoblastic change","volume":"30","author":"Chen K","year":"2017","unstructured":"Chen K, He YY. The morphological characteristics and prognosis of bone marrow cells in chronic myelogenous leukemia with acute granulosis and acute lymphoblastic change. Chin. J. Clin. Res. 30(8), 3 (2017).","journal-title":"Chin. J. Clin. Res."},{"issue":"6","key":"e_1_3_5_67_2","first-page":"479","article-title":"A clinical study on second-generation tyrosine kinase inhibitors as first-and second-line treatments in chronic myeloid leukemia","volume":"23","author":"Chen H","year":"2017","unstructured":"Chen H, Jiang YQ, Shen YF A clinical study on second-generation tyrosine kinase inhibitors as first-and second-line treatments in chronic myeloid leukemia. Chin. J. Biomed. Eng. 23(6), 479\u2013483 (2017).","journal-title":"Chin. J. Biomed. Eng."},{"issue":"10","key":"e_1_3_5_68_2","first-page":"997","article-title":"Clinical study of dasatinib in the treatment of patients with chronic myeloid leukemia in different clinical stages","volume":"24","author":"Dai LX","year":"2018","unstructured":"Dai LX, Tu XQ, Cai BB. Clinical study of dasatinib in the treatment of patients with chronic myeloid leukemia in different clinical stages. J. Chin. Oncol. 24(10), 997\u20131001 (2018).","journal-title":"J. Chin. Oncol."},{"issue":"4","key":"e_1_3_5_69_2","first-page":"409","article-title":"CHG pre-excitation regimen combined with imatinib mesylate in the treatment of acute myeloid transformation of chronic myeloid leukemia","volume":"28","author":"Zhang C","year":"2014","unstructured":"Zhang C. CHG pre-excitation regimen combined with imatinib mesylate in the treatment of acute myeloid transformation of chronic myeloid leukemia. J. Chin. Pract. Diagn. Ther. 28(4), 409\u2013410 (2014).","journal-title":"J. Chin. Pract. Diagn. Ther."},{"key":"e_1_3_5_70_2","first-page":"2014","article-title":"Treatment overview and medication compliance analysis of 140 patients with chronic myeloid leukemia","volume":"48","author":"Pan CY","year":"2019","unstructured":"Pan CY, Li YJ, Li MX Treatment overview and medication compliance analysis of 140 patients with chronic myeloid leukemia. Chongqing Med. 48, 2014\u20132017 (2019).","journal-title":"Chongqing Med."},{"key":"e_1_3_5_71_2","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang Q","year":"2011","unstructured":"Jiang Q, Xu LP, Liu DH Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117, 3032\u20133040 (2011).","journal-title":"Blood"},{"key":"e_1_3_5_72_2","first-page":"2405","article-title":"Efficacy of allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia","volume":"38","author":"Xu XH","year":"2012","unstructured":"Xu XH, Xu Y, Ouyang YJ Efficacy of allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Jiangsu Med. J. 38, 2405\u20132407 (2012).","journal-title":"Jiangsu Med. J."},{"issue":"3","key":"e_1_3_5_73_2","first-page":"438","article-title":"Analysis of the effect of HLA matching on chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation","volume":"31","author":"Zhang Y","year":"2011","unstructured":"Zhang Y, Chen YK, Fan ZP Analysis of the effect of HLA matching on chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation. J. Southern Med. Univ. 31(3), 438\u2013442 (2011).","journal-title":"J. Southern Med. Univ."},{"issue":"5","key":"e_1_3_5_74_2","first-page":"458","article-title":"Clinical observation of 52 cases of acute and chronic leukemia treated with allogeneic peripheral blood stem cell transplantation","volume":"21","author":"Zhang X","year":"2008","unstructured":"Zhang X, Chen XH, Gao L Clinical observation of 52 cases of acute and chronic leukemia treated with allogeneic peripheral blood stem cell transplantation. J. Clin. Hematol. 21(5), 458\u2013460 (2008).","journal-title":"J. Clin. Hematol."},{"issue":"1","key":"e_1_3_5_75_2","first-page":"55","article-title":"Analysis of curative effect of related allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia in 30 cases","volume":"28","author":"Xia LH","year":"2007","unstructured":"Xia LH, Fang J, Liu F Analysis of curative effect of related allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia in 30 cases. Chin. J. Organ Transplant. 28(1), 55\u201356 (2007).","journal-title":"Chin. J. Organ Transplant."},{"key":"e_1_3_5_76_2","first-page":"2618","article-title":"Allogeneic hematopoietic stem cell transplantation from HLA-contracted donors for treatment of 40 cases of chronic myeloid leukemia","volume":"13","author":"Wang XB","year":"2009","unstructured":"Wang XB, Liu HL, Geng LQ Allogeneic hematopoietic stem cell transplantation from HLA-contracted donors for treatment of 40 cases of chronic myeloid leukemia. Chin. J. Tissue Eng. Res. 13, 2618\u20132622 (2009).","journal-title":"Chin. J. Tissue Eng. Res."},{"issue":"29","key":"e_1_3_5_77_2","first-page":"3554","article-title":"Clinical observation of imatinib combined with stem cell transplantation in the treatment of chronic myeloid leukemia","volume":"42","author":"Li MX","year":"2013","unstructured":"Li MX, Wang JS, Zhang Y, Sun ZQ, Zhao P, Lu YH. Clinical observation of imatinib combined with stem cell transplantation in the treatment of chronic myeloid leukemia. Chongqing Med. 42(29), 3554\u20133556 (2013).","journal-title":"Chongqing Med."},{"key":"e_1_3_5_78_2","first-page":"149","article-title":"Preliminary analysis of the efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in the treatment of advanced chronic myeloid leukemia","volume":"19","author":"Song AX","year":"2011","unstructured":"Song AX, Yang DL, Wei JL Preliminary analysis of the efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in the treatment of advanced chronic myeloid leukemia. J. Exp. Hematol. 19, 149\u2013153 (2011).","journal-title":"J. Exp. Hematol."},{"issue":"6","key":"e_1_3_5_79_2","first-page":"349","article-title":"Treatment of advanced chronic myeloid leukemia with non-blood cord blood transplantation","volume":"21","author":"Zhang LL","year":"2012","unstructured":"Zhang LL, Liu HL, Geng LQ Treatment of advanced chronic myeloid leukemia with non-blood cord blood transplantation. J. Leuk. Lymphoma 21(6), 349\u2013352 (2012).","journal-title":"J. Leuk. Lymphoma"},{"issue":"2","key":"e_1_3_5_80_2","first-page":"73","article-title":"HLA haploidentical hematopoietic stem cell transplantation for treatment of advanced chronic myeloid leukemia","volume":"33","author":"Zhao YL","year":"2012","unstructured":"Zhao YL, Zhang JP, Ji SQ HLA haploidentical hematopoietic stem cell transplantation for treatment of advanced chronic myeloid leukemia. Chin. J. Organ Transplant. 33(2), 73\u201376 (2012).","journal-title":"Chin. J. Organ Transplant."},{"key":"e_1_3_5_81_2","first-page":"126","article-title":"Retrospective analysis of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia","volume":"35","author":"Zhou M","year":"2014","unstructured":"Zhou M, Sha XS, Qiu HY Retrospective analysis of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Chin. J. Hematol. 35, 126\u2013128 (2014).","journal-title":"Chin. J. Hematol."},{"issue":"1","key":"e_1_3_5_82_2","first-page":"44","article-title":"Effect of stratified intervention therapy after allogeneic hematopoietic stem cell transplantation in chronic myelogenous leukemia","volume":"31","author":"Feng SQ","year":"2018","unstructured":"Feng SQ, Liu ZB, Yao YH Effect of stratified intervention therapy after allogeneic hematopoietic stem cell transplantation in chronic myelogenous leukemia. J. Clin. Hematol. 31(1), 44\u201348 (2018).","journal-title":"J. Clin. Hematol."},{"key":"e_1_3_5_83_2","first-page":"432","article-title":"Imatinib first-line treatment of chronic myeloid leukemia patients in chronic phase-a single-center retrospective analysis","volume":"43","author":"Li F","year":"2016","unstructured":"Li F, Zhang XJ, Zhang RY Imatinib first-line treatment of chronic myeloid leukemia patients in chronic phase-a single-center retrospective analysis. Chin. J. Clin. Oncol. 43, 432\u2013437 (2016).","journal-title":"Chin. J. Clin. Oncol."},{"issue":"4","key":"e_1_3_5_84_2","first-page":"257","article-title":"Efficacy observation and cost analysis of HLA-contracted allogeneic hematopoietic stem cell transplantation for the first chronic phase of chronic myeloid leukemia","volume":"26","author":"Wang XB","year":"2009","unstructured":"Wang XB, Sun ZM, Liu HL Efficacy observation and cost analysis of HLA-contracted allogeneic hematopoietic stem cell transplantation for the first chronic phase of chronic myeloid leukemia. J. Clin. Intern. Med. 26(4), 257\u2013260 (2009).","journal-title":"J. Clin. Intern. Med."},{"key":"e_1_3_5_85_2","first-page":"9268","article-title":"The efficacy and quality of life follow-up of 34 patients with chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Wang WQ","year":"2007","unstructured":"Wang WQ, Bai QX, Chen XQ The efficacy and quality of life follow-up of 34 patients with chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation. Chin. J. Tissue Eng. Res. 11, 9268\u20139271 (2007).","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"e_1_3_5_86_2","first-page":"10184","article-title":"Differences in efficacy and safety of imatinib mesylate and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia in chronic phase","volume":"12","author":"Zou J","year":"2008","unstructured":"Zou J, Li WM, Xia LH Differences in efficacy and safety of imatinib mesylate and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia in chronic phase. Chin. J. Tissue Eng. Res. 12, 10184\u201310188 (2008).","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"e_1_3_5_87_2","first-page":"349","article-title":"BU-CTX2 pretreatment regimen for the treatment of 60 cases of leukemia with allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Zhu KE","year":"2002","unstructured":"Zhu KE, Xu Y, Zhong J, Chen ST, Zeng HL. BU-CTX2 pretreatment regimen for the treatment of 60 cases of leukemia with allogeneic hematopoietic stem cell transplantation. Chin. J. Hematol. 23, 349\u2013352 (2002).","journal-title":"Chin. J. Hematol."},{"issue":"2","key":"e_1_3_5_88_2","first-page":"93","article-title":"Detection of minimal residual disease after unrelated allogeneic bone marrow transplantation in chronic myeloid leukemia by RT-nest-PCR method","volume":"20","author":"Xue J","year":"2007","unstructured":"Xue J, Wang YG, Huang H, Lin MF. Detection of minimal residual disease after unrelated allogeneic bone marrow transplantation in chronic myeloid leukemia by RT-nest-PCR method. J. Clin. Hematol. 20(2), 93\u201395 (2007).","journal-title":"J. Clin. Hematol."},{"issue":"11","key":"e_1_3_5_89_2","first-page":"589","article-title":"Effect of interferon alpha on the prognosis of allogeneic bone marrow transplantation in patients with chronic myeloid leukemia","volume":"22","author":"Xu LP","year":"2001","unstructured":"Xu LP, Guo NL, Huang XJ Effect of interferon alpha on the prognosis of allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Chin. J. Hematol. 22(11), 589\u2013591 (2001).","journal-title":"Chin. J. Hematol."},{"issue":"49","key":"e_1_3_5_90_2","first-page":"88","article-title":"Efficacy and prognostic factors analysis of allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia","volume":"51","author":"Xu MZ","year":"2011","unstructured":"Xu MZ, Sun AN, Wu DP Efficacy and prognostic factors analysis of allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Shandong Med. J. 51(49), 88\u201390 (2011).","journal-title":"Shandong Med. J."},{"key":"e_1_3_5_91_2","first-page":"20","article-title":"Standard dose and reduced dose preconditioning peripheral blood stem cell transplantation in the treatment of chronic myeloid leukemia clinical research","volume":"1","author":"Wang JM","year":"2007","unstructured":"Wang JM, Zhang WP, Chen L Standard dose and reduced dose preconditioning peripheral blood stem cell transplantation in the treatment of chronic myeloid leukemia clinical research. Chin. J. Pract. Intern. Med. S1, 20 (2007).","journal-title":"Chin. J. Pract. Intern. Med."},{"key":"e_1_3_5_92_2","first-page":"545","article-title":"Efficacy and prognostic factors analysis of allogeneic hematopoietic stem cell transplantation from HLA-contracted donors in the treatment of chronic myeloid leukemia","volume":"28","author":"Tong XZ","year":"2006","unstructured":"Tong XZ, Li J, Tan EX Efficacy and prognostic factors analysis of allogeneic hematopoietic stem cell transplantation from HLA-contracted donors in the treatment of chronic myeloid leukemia. Chin. J. Clin. Oncol. 28, 545\u2013548 (2006).","journal-title":"Chin. J. Clin. Oncol."},{"key":"e_1_3_5_93_2","first-page":"295","article-title":"Clinical study of allogeneic peripheral blood stem cell transplantation in the treatment of chronic myeloid leukemia","volume":"26","author":"Song XM","year":"2001","unstructured":"Song XM, Wang JM, Ju XP Clinical study of allogeneic peripheral blood stem cell transplantation in the treatment of chronic myeloid leukemia. Med. J. Chin. People\u2019s Liberation Army 26, 295\u2013297 (2001).","journal-title":"Med. J. Chin. People\u2019s Liberation Army"},{"key":"e_1_3_5_94_2","first-page":"309","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia","volume":"5","author":"Qian SX","year":"2009","unstructured":"Qian SX, Wu HX, Hong M Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Chin. J. Organ Transplant. 5, 309\u2013310 (2009).","journal-title":"Chin. J. Organ Transplant."},{"issue":"11","key":"e_1_3_5_95_2","first-page":"1227","article-title":"Analysis of curative effect of hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia","volume":"24","author":"Liu QF","year":"2004","unstructured":"Liu QF, Fan ZP, Sun J Analysis of curative effect of hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. J. Southern Med. Univ. 24(11), 1227\u20131229 (2004).","journal-title":"J. Southern Med. Univ."},{"key":"e_1_3_5_96_2","first-page":"216","article-title":"A clinical comparative study of related allogeneic hematopoietic stem cell transplantation and STI571 in the treatment of chronic myeloid leukemia","volume":"20","author":"Li WM","year":"2007","unstructured":"Li WM, Xia LH, You Y, Liu XY, Zhong ZD, Zou P. A clinical comparative study of related allogeneic hematopoietic stem cell transplantation and STI571 in the treatment of chronic myeloid leukemia. J. Clin. Hematol. 20, 216\u2013219 (2007).","journal-title":"J. Clin. Hematol."},{"issue":"8","key":"e_1_3_5_97_2","first-page":"607","article-title":"Effect of interferon alpha before transplantation on the prognosis of unrelated allogeneic bone marrow transplantation in patients with chronic myeloid leukemia","volume":"28","author":"Huang L","year":"2006","unstructured":"Huang L, Huang H, Cai Z Effect of interferon alpha before transplantation on the prognosis of unrelated allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Zhejiang Med. J. 28(8), 607\u2013609 (2006).","journal-title":"Zhejiang Med. J."},{"issue":"7","key":"e_1_3_5_98_2","first-page":"389","article-title":"HLA-related allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the first chronic phase of 51 cases","volume":"26","author":"He Y","year":"2005","unstructured":"He Y, Feng SZ, Wang M HLA-related allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the first chronic phase of 51 cases. Chin. J. Hematol. 26(7), 389\u2013392 (2005).","journal-title":"Chin. J. Hematol."},{"issue":"4","key":"e_1_3_5_99_2","first-page":"374","article-title":"The clinical significance of BCR-ABL fusion gene detection and pretreatment in patients with chronic myeloid leukemia before and after transplantation","volume":"6","author":"Gao XD","year":"2007","unstructured":"Gao XD, Wu W, Zhao WL, Tang W, Shen ZX, Hu J. The clinical significance of BCR-ABL fusion gene detection and pretreatment in patients with chronic myeloid leukemia before and after transplantation. J. Diagn. Concepts Pract. 6(4), 374\u2013375 (2007).","journal-title":"J. Diagn. Concepts Pract."},{"key":"e_1_3_5_100_2","first-page":"373","article-title":"Nonmyeloablative peripheral blood stem cell transplantation for chronic myeloid leukemia in chronic and accelerated phases","volume":"16","author":"Ding JH","year":"2008","unstructured":"Ding JH, Ma Y, Chen BA Nonmyeloablative peripheral blood stem cell transplantation for chronic myeloid leukemia in chronic and accelerated phases. J. Exp. Hematol. 16, 373\u2013376 (2008).","journal-title":"J. Exp. Hematol."},{"key":"e_1_3_5_101_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11096-014-0036-5","article-title":"A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies","volume":"37","author":"Cai X","year":"2014","unstructured":"Cai X, Wei J, He Y A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. Int. J. Clin. Pharm. 37, 44\u201352 (2014).","journal-title":"Int. J. Clin. Pharm."},{"key":"e_1_3_5_102_2","first-page":"3035","article-title":"Efficacy analysis of imatinib mesylate and allogeneic hematopoietic stem cell transplantation in the chronic phase of chronic myeloid leukemia","volume":"93","author":"Gao GL","year":"2013","unstructured":"Gao GL, Xu N, Zhou X Efficacy analysis of imatinib mesylate and allogeneic hematopoietic stem cell transplantation in the chronic phase of chronic myeloid leukemia. Natl Med. J. China 93, 3035\u20133039 (2013).","journal-title":"Natl Med. J. China"},{"key":"e_1_3_5_103_2","first-page":"S158","article-title":"Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"51","author":"Xu L","year":"2016","unstructured":"Xu L, Xu Z, Zhang X, Chen H, Chen Y, Huang X. Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia. Bone Marrow Transplant. 51, S158\u2013S159 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_5_104_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00277-010-1081-3","article-title":"Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China","volume":"90","author":"Liu QF","year":"2011","unstructured":"Liu QF, Xu XJ, Chen YK Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann. Hematol. 90, 331\u2013341 (2011).","journal-title":"Ann. Hematol."},{"issue":"24","key":"e_1_3_5_105_2","first-page":"4742","article-title":"Comparison of the effects of related allogeneic hematopoietic stem cell transplantation and STI571 in the treatment of non-chronic stage chronic myeloid leukemia","volume":"11","author":"Li WM","year":"2007","unstructured":"Li WM, Xia LH, You Y, Liu XY, Zhong ZD, Zou P. Comparison of the effects of related allogeneic hematopoietic stem cell transplantation and STI571 in the treatment of non-chronic stage chronic myeloid leukemia. Chin. J. Tissue Eng. Res. 11(24), 4742\u20134746 (2007).","journal-title":"Chin. J. Tissue Eng. Res."},{"issue":"3","key":"e_1_3_5_106_2","first-page":"253","article-title":"Allogeneic hematopoietic stem cell transplantation in the treatment of advanced chronic myelogenous leukemia \u2013 efficacy analysis of transplantation of non-blood cord blood and sibling donors","volume":"35","author":"Lu YJ","year":"2014","unstructured":"Lu YJ, Sun ZM, Liu HL Allogeneic hematopoietic stem cell transplantation in the treatment of advanced chronic myelogenous leukemia \u2013 efficacy analysis of transplantation of non-blood cord blood and sibling donors. Chin. J. Hematol. 35(3), 253\u2013255 (2014).","journal-title":"Chin. J. Hematol."},{"key":"e_1_3_5_107_2","first-page":"203","article-title":"Investigation of health-related quality of life in patients with chronic myeloid leukemia in the chronic phase","volume":"36","author":"Shu M","year":"2020","unstructured":"Shu M, Sun Y, Wang XD. Investigation of health-related quality of life in patients with chronic myeloid leukemia in the chronic phase. J. Modern Med. Health 36, 203\u2013206 (2020).","journal-title":"J. Modern Med. Health"},{"key":"e_1_3_5_108_2","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2019-129030","article-title":"Final development of the first generic quality of life and symptoms measure specific for hematological malignancies: the HM-PRO","volume":"134","author":"Goswami P","year":"2019","unstructured":"Goswami P, Ionova T, Oliva EN Final development of the first generic quality of life and symptoms measure specific for hematological malignancies: the HM-PRO. Blood 134, 3484\u20133484 (2019).","journal-title":"Blood"},{"key":"e_1_3_5_109_2","first-page":"234","article-title":"The Chinese version of FACT-Leu scale is used to assess the quality of life of CML patients and analysis of influencing factors","volume":"14","author":"Wang YL","year":"2019","unstructured":"Wang YL, Chen FJ, Luo YQ, Leng YM, Zhu HL. The Chinese version of FACT-Leu scale is used to assess the quality of life of CML patients and analysis of influencing factors. J. Chengdu Med. Coll. 14, 234\u2013239 (2019).","journal-title":"J. Chengdu Med. Coll."},{"issue":"3","key":"e_1_3_5_110_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.31082","article-title":"Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome\u2013positive chronic myeloid leukemia patients resistant or intolerant to prior therapy","volume":"124","author":"Kantarjian HM","year":"2018","unstructured":"Kantarjian HM, Mamolo CM, Gambacorti-Passerini C Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome\u2013positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer 124(3), 587\u2013595 (2018).","journal-title":"Cancer"},{"issue":"11","key":"e_1_3_5_111_2","first-page":"59","article-title":"Analysis of the budgetary impact of the inclusion of nilotinib in medical insurance for the treatment of imatinib-resistant or intolerant myeloid leukemia patients","volume":"37","author":"Huang CF","year":"2018","unstructured":"Huang CF, Shen LJ, Liu YH. Analysis of the budgetary impact of the inclusion of nilotinib in medical insurance for the treatment of imatinib-resistant or intolerant myeloid leukemia patients. Chin. Health Econ. 37(11), 59\u201363 (2018).","journal-title":"Chin. Health Econ."},{"key":"e_1_3_5_112_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","article-title":"Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China","volume":"38","author":"Li N","year":"2018","unstructured":"Li N, Zheng B, Cai HF Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China. Clin. Drug Invest. 38, 79\u201386 (2018).","journal-title":"Clin. Drug Invest."},{"key":"e_1_3_5_113_2","first-page":"721","article-title":"Investigation and analysis of the incidence of chronic myeloid leukemia and current diagnosis and treatment models in 15 hospitals in China","volume":"30","author":"Wang JX","year":"2009","unstructured":"Wang JX, Huang XJ, Wu DP Investigation and analysis of the incidence of chronic myeloid leukemia and current diagnosis and treatment models in 15 hospitals in China. Chin. J. Hematol. 30, 721\u2013725 (2009).","journal-title":"Chin. J. Hematol."},{"issue":"6","key":"e_1_3_5_114_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5582\/ddt.2019.01093","article-title":"\u201c4+ 7\u201d city drug volume-based purchasing and using pilot program in China and its impact","volume":"13","author":"Tang M","year":"2019","unstructured":"Tang M, He J, Chen M \u201c4+ 7\u201d city drug volume-based purchasing and using pilot program in China and its impact. Drug Discoveries & Therapeutics 13(6), 365\u20139 (2019).","journal-title":"Drug Discoveries & Therapeutics"},{"issue":"12","key":"e_1_3_5_115_2","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang X","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12), 3123\u20133127 (2012).","journal-title":"Cancer"},{"issue":"21","key":"e_1_3_5_116_2","first-page":"1","article-title":"United States Life Tables, 2006","volume":"58","author":"Arias E","year":"2010","unstructured":"Arias E. United States Life Tables, 2006. Natl Vital Stat. Rep. 58(21), 1\u201340 (2010).","journal-title":"Natl Vital Stat. Rep."},{"key":"e_1_3_5_117_2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2147\/CMAR.S237467","article-title":"Validation of the EUTOS long-term survival score in Chinese chronic myeloid leukemia patients treated with imatinib: a multicenter real-world study","volume":"12","author":"Yang X","year":"2020","unstructured":"Yang X, Bai Y, Shi M Validation of the EUTOS long-term survival score in Chinese chronic myeloid leukemia patients treated with imatinib: a multicenter real-world study. Cancer Manag. Res. 12, 1293\u20131301 (2020).","journal-title":"Cancer Manag. Res."},{"issue":"10","key":"e_1_3_5_118_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and d PCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori S","year":"2015","unstructured":"Mori S, Vagge E, Le Courted P Age and d PCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am. J. Hematol. 90(10), 910\u2013914 (2015).","journal-title":"Am. J. Hematol."},{"key":"e_1_3_5_119_2","first-page":"2485","article-title":"Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy","volume":"8","author":"Xia L","year":"2015","unstructured":"Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. Onco Targets Ther. 8, 2485\u20132492 (2015).","journal-title":"Onco Targets Ther."},{"issue":"5","key":"e_1_3_5_120_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian HM","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5), 1123\u20131129 (2012).","journal-title":"Blood"},{"key":"e_1_3_5_121_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus A","year":"2009","unstructured":"Hochhaus A, O\u2019Brien S, Guilhot F Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054\u20131061 (2009).","journal-title":"Leukemia"},{"issue":"4","key":"e_1_3_5_122_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel AB","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol. Oncol. Clin. North Am. 31(4), 589\u2013612 (2017).","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"e_1_3_5_123_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"Mealing S","year":"2013","unstructured":"Mealing S, Barcena L, Hawkins N The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp. Hematol. Oncol. 2(1), 1\u20139 (2013).","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"e_1_3_5_124_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/heartjnl-2020-318251","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease","volume":"107","author":"Leong D","year":"2021","unstructured":"Leong D, Aghel N, Hillis C Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart 107(8), 667\u2013673 (2021).","journal-title":"Heart"},{"issue":"4","key":"e_1_3_5_125_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/17512433.2021.1894129","article-title":"Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies","volume":"14","author":"Wang Z","year":"2021","unstructured":"Wang Z, Jiang L, Yan H, Xu Z, Luo P. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Review of Clinical Pharmacology 14(4), 445\u201356 (2021).","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"1","key":"e_1_3_5_126_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000323662","article-title":"Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"126","author":"Oyekunle A","year":"2011","unstructured":"Oyekunle A, Klyuchnikov E, Ocheni S Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematologica 126(1), 30\u20139 (2011).","journal-title":"Acta Haematologica"},{"issue":"1","key":"e_1_3_5_127_2","first-page":"64","article-title":"Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial","volume":"100","author":"Cortes J","year":"2015","unstructured":"Cortes J, Kim DW, Pinilla-Ibarz J Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial. Haematologica 100(Suppl. 1), 64 (2015).","journal-title":"Haematologica"},{"issue":"15","key":"e_1_3_5_128_2","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini FE","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim DW Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123(15), 2875\u20132880 (2017).","journal-title":"Cancer"},{"issue":"8","key":"e_1_3_5_129_2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","article-title":"Ponatinib: accelerated disapproval","volume":"20","author":"Gainor JF","year":"2015","unstructured":"Gainor JF, Chabner BA. Ponatinib: accelerated disapproval. The Oncologist. 20(8), 847 (2015).","journal-title":"The Oncologist."},{"issue":"377","key":"e_1_3_5_130_2","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human pluripotent stem cells","volume":"9","author":"Sharma A","year":"2017","unstructured":"Sharma A, Burridge PW, McKeithan WL High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human pluripotent stem cells. Sci. Transl. Med. 9(377), 2584 (2017).","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"e_1_3_5_131_2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh AP","year":"2019","unstructured":"Singh AP, Glennon MS, Umbarkar P Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc. Res. 115(5), 966\u2013977 (2019).","journal-title":"Cardiovasc. Res."},{"key":"e_1_3_5_132_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib","volume":"316","author":"Singh AP","year":"2020","unstructured":"Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib. Int. J. Cardiol. 316, 214\u2013221 (2020).","journal-title":"Int. J. Cardiol."},{"issue":"24","key":"e_1_3_5_133_2","first-page":"7787","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler R","year":"2021","unstructured":"Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur. Rev. Med. Pharmacol. Sci. 25(24), 7787\u20137798 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2022-0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:15:18Z","timestamp":1679231718000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":131,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2217\/cer-2022-0032"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0032","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}